NVCR News and Press, NovoCure Limited From 10/20/22

Campaign urges healthcare providers to harness the versatile power of electric fields to outsmart solid tumors Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a dist...

The number one fact in play right now for investors is risk aversion. According to Bank of America strategists, professional money managers are currently sitting on their highest cash allocation levels ever. According Sentimentrader.com, large investors are currently sitting on their largest ...

You only have to do two things to make a fortune investing in stocks. First, buy the right stock. Second, buy it at the right time. That's it. Unfortunately, those two simple steps can be very difficult to pull off. However, they don't always have to be so challenging. It's possible to ...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results f...

As they enter the final quarter of calendar year 2022, many investors are probably wondering when the sell-off will end. This year has tested the patience of even the most experienced investors as the tech-heavy Nasdaq Composite is down over 30% from its all-time high while the S&...

Summary NovoCure faces a host of growth options along two key vectors: new geographies and other cancer applications. Despite short-term de-growth in active patients, long-term tailwinds to market share justify the company's superior multiple expansion. A conservative valuatio...

Oncology company Novocure ( NASDAQ: NVCR ) on Wednesday announced the creation of a central nervous system focused cancers franchise. NVCR's chief development officer Frank Leonard was named president of the new organization, U.S. CNS Cancers Franchise. The franchise w...

Frank Leonard is appointed President, CNS Cancers U.S. Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Novocu...

Summary NovoCure has maintained a large amount of institutional investors since IPO in 2015, and has nearly 78% of shares held by institutions today. Insider Ownership is high as well at 14% indicating employees have conviction in the long-term outlook of the company. NovoCure...

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle a...